Medtronic Q3 FY26 Earnings Surge on Cardiac Ablation and Diabetes Growth
Medtronic plc (MDT) reported a robust third-quarter performance for fiscal 2026, with revenue climbing 8.7% to $9.0 billion. The growth was driven by exceptional demand in cardiac ablation solutions and diabetes care, underscoring the company's technological edge in medical devices.
The cardiac ablation division delivered an 80% revenue surge, powered by adoption of pulsed field ablation (PFA) technology. U.S. sales jumped 137%, while regulatory milestones like the CE Mark for Sphere-360 device position Medtronic for sustained dominance in arrhythmia treatment.
Diabetes revenue grew 8.3% internationally, reflecting strong uptake of Medtronic's monitoring systems. Operating profit reached $1.464 billion, demonstrating the company's ability to convert innovation into margin expansion.